A5040530977- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Neuroblastoma Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neutropenia and Cancer Infections
- Multiple and Secondary Primary Cancers
- Male Breast Health Studies
- Gastric Cancer Management and Outcomes
- Angiogenesis and VEGF in Cancer
- Colorectal Cancer Surgical Treatments
- Peripheral Nerve Disorders
- Cancer Treatment and Pharmacology
- Gastrointestinal Tumor Research and Treatment
- Lymphoma Diagnosis and Treatment
- Orthopedic Surgery and Rehabilitation
- Medical Imaging and Analysis
- Frailty in Older Adults
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2024
Istituto Oncologico Veneto
2017-2021
Policlinico Umberto I
2015-2017
Sapienza University of Rome
2012-2016
3506 Background: Despite advances in molecular segmentation of metastatic colorectal cancer (mCRC), beyond RAS status therapeutic actionability remains confined to the limited subgroups ERBB2 amplified, BRAF mutated and MSI-H patients. Optimization available treatments is therefore warranted. Rechallenge with anti-EGFR monoclonal antibodies often empirically used some benefit as late-line therapy. We previously found that mutant EGFR ectodomain clones, which emerge blood during blockade,...
Study Type – Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does study add? Primary renal synovial sarcoma is a very rare neoplasm. Since 2000, when this tumour was first described, only case reports have been published in medical literature. This to describe clinical pathological features primary it found relationship between these characteristics. Median overall disease‐free survival were reported, risk relapse for patients with non‐metastatic disease at...
Background Immune checkpoint inhibitors (ICIs) are the new standard of care in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Since tumor response dynamic parameters already shown a strong association with survival outcomes patients mCRC treated first-line therapy, we investigated early shrinkage (ETS) and depth (DoR) MSI-H/dMMR ICIs. Methods This is retrospective, multicenter, cohort study dMMR and/or MSI-high ICIs...
Well-differentiated lung neuroendocrine tumours (Lu-NETs), classified as typical (TC) and atypical (AC) carcinoids, represent 30% of NETs. Angiogenesis plays an essential role in NET development progression. A higher vascular network is a marker differentiation, with positive prognostic implications. Materials Methods: We retrospectively evaluated microvessel density (MVD) by CD34 immunohistochemical (IHC) staining hypoxia IHC for Hypoxia-inducible factor 1α (HIF-1α), comparing right-...
660 Background: In the NAPOLI I phase III trial, Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) showed better outcome compared to 5FU/LV in patients with metastatic Pancreatic Cancer (MPC) progressed 1st- line gemcitabine-based therapy. Aim of this study is explore real-world efficacy and safety 5FU/LV-nal-IRI by a compassionate use programme identify potential prognostic factors that could affect survival setting. Methods: This retrospective multi-center...
This study was undertaken to review a single-institution cohort of patients with metastatic colorectal cancer undergoing lung resection after multidisciplinary evaluation and investigate the main prognostic factors for survival.Medical records 129 metastasectomy curative intent from 2001 2017 were reviewed. Tissue samples primary tumor analyzed multiplex genotyping system detection mutations in RAS BRAF genes. Survival analyses carried out by Kaplan-Meier method. Univariate multivariable...
e15042 Background: Chemotherapy (CT) associated with angiogenesis inhibitor bevacizumab (bev) is a standard first line treatment in metastatic colorectal cancer (mCRC). Among adverse events related to bev, anal canal ulcers have never been extensively described. The aim of our study was evaluate symptomatic development and its impact on clinical practice proctologic management. Methods: We retrospectively reviewed records 601 consecutive mCRC patients (pts) undergoing CT from January 2010...
11591 Background: FOLFOXIRI/bev is a valid option as first-line therapy for unresectable mCRC. TRIBE and TRIBE2 trials reported better activity efficacy of the triplet/bev when compared with doublets/bev at price higher incidence chemo-related toxicities, including neutropenia (N). Here we aim providing detailed description this adverse event, occurrence febrile (FN) use granulocyte-colony stimulating factors (G-CSFs), in order to estimate clinical relevance N during FOLFOXIRI/bev. Methods:...
11552 Background: About 50% of diagnoses colorectal cancer (CRC) occur in patients (pts) older than 70 years. Though a comprehensive geriatric assessment (CGA) is recommended for proper management pts, there still no consensus on the best form assessment. We investigated possible prognostic factors elderly metastatic (m)CRC pts real-world setting, focusing role oncological-multidimensional index (onco-MPI). Methods: Pts aged ≥ years with mCRC referred to Medical Oncology 1 Unit from May 2010...